You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
In the next round of the eMERGE program, NIH is supporting development of methodologies for integrating genotypic and phenotypic risk scoring into clinical care.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
Ten sites across the US will seek to integrate genomic risk assessment into clinical care, with a focus on diverse populations.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.
In Phase 2 pilots, four healthcare organizations helped HL7 refine its FHIR Genomics specification but uncovered many remaining hurdles to true interoperability.
AMELIE demonstrated greater accuracy and speed than previous methods in suggesting relevant genetic variants for diagnosing monogenic disorders.
The companies will bundle claims analytics, clinical decision support, provider education, and other pharmacist-driven support for prescribers.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.